نتایج جستجو برای: hdac inhibitor

تعداد نتایج: 213269  

Journal: :The Biochemical journal 2008
Nagma Khan Michael Jeffers Sampath Kumar Craig Hackett Ferenc Boldog Nicholai Khramtsov Xiaozhong Qian Evan Mills Stanny C Berghs Nessa Carey Paul W Finn Laura S Collins Anthony Tumber James W Ritchie Peter Buhl Jensen Henri S Lichenstein Maxwell Sehested

The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription. While HDACs can be subdivided into three main classes, the class I, class II and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms tha...

Journal: :Molecular cancer therapeutics 2006
Laura R Saunders Eric Verdin

Inhibitors of histone deacetylases (HDAC) show significant promise as targeted anticancer agents against a variety of hematologic and solid tumors. HDAC inhibitors arrest the growth of primary cells, but they induce apoptosis or differentiation of tumor cells. Although the precise mechanism is unknown, differences in cell cycle checkpoints and chromatin structure may be responsible. Cellular po...

2014
F. A. Schroeder C. Wang G. C. Van de Bittner R. Neelamegam W. R. Takakura A. Karunakaran H. Y. Wey S. A. Reis J. Gale Y. L. Zhang E. B. Holson S. J. Haggarty J. M. Hooker

Histone deacetylase (HDAC) enzymes have been demonstrated as critical components in maintaining chromatin homeostasis, CNS development, and normal brain function. Evidence in mouse models links HDAC expression to learning, memory, and mood-related behaviors; small molecule HDAC inhibitor tool compounds have been used to demonstrate the importance of specific HDAC subtypes in modulating CNS-dise...

2016
Somy Yoon Gwang Hyeon Eom

Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states. HDAC inhibitors have been highlighted as a novel category of anti-cancer drugs. To date, four HDAC inhibit...

2013
Usman Sumo Friend Tambunan Ridla Bakri Tirtana Prasetia Arli Aditya Parikesit Djati Kerami

Cervical cancer is second most common cancer in woman worldwide. Cervical cancer caused by human papillomavirus (HPV) oncogene. Inhibition of histone deacetylase (HDAC) activity has been known as a potential strategy for cancer therapy. SAHA is an HDAC inhibitor that has been used in cancer therapy but still has side effects. SAHA modification proposed to minimize side effects. Triazole attachm...

Journal: :Molecular cancer therapeutics 2011
Yali Kong Mira Jung Kan Wang Scott Grindrod Alfredo Velena Sung A Lee Sivanesan Dakshanamurthy Yonghong Yang Matthew Miessau Chaoyi Zheng Anatoly Dritschilo Milton L Brown

Inhibitors of histone deacetylases (HDAC) are an important emerging class of drugs for the treatment of cancers. HDAC inhibitors are currently under evaluation in clinical trials as single agents and as sensitizers in combinations with chemotherapies and radiation therapy. Although these drugs have important effects on cancer cell growth and functions, the mechanisms underlying HDAC inhibitor a...

Journal: :Circulation research 2012
Maria A Cavasin Kim Demos-Davies Todd R Horn Lori A Walker Douglas D Lemon Nicholas Birdsey Mary C M Weiser-Evans Julie Harral David C Irwin Adil Anwar Michael E Yeager Min Li Peter A Watson Raphael A Nemenoff Peter M Buttrick Kurt R Stenmark Timothy A McKinsey

RATIONALE Histone deacetylase (HDAC) inhibitors are efficacious in models of hypertension-induced left ventricular heart failure. The consequences of HDAC inhibition in the context of pulmonary hypertension with associated right ventricular cardiac remodeling are poorly understood. OBJECTIVE This study was performed to assess the utility of selective small-molecule inhibitors of class I HDACs...

2011
Yali Kong Mira Jung Kan Wang Scott Grindrod Alfredo Velena Sung A. Lee Sivanesan Dakshanamurthy Yonghong Yang Matthew Miessau Chaoyi Zheng Milton L. Brown

Inhibitors of histone deacetylases (HDAC) are an important emerging class of drugs for the treatment of cancers. HDAC inhibitors are currently under evaluation in clinical trials as single agents and as sensitizers in combinations with chemotherapies and radiation therapy. Although these drugs have important effects on cancer cell growth and functions, the mechanisms underlying HDAC inhibitor a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید